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Introduction: The epidermal growth factor receptor (EGFR) gene
status including tyrosine kinase domain somatic mutations, increased
copy number, and protein overexpression are reported to be associated
with response to EGFR tyrosine kinase inhibitors in patients with
non-small cell lung cancer. The purpose of this study was to elucidate
the prevalence of activated EGFR gene and the association between
mutation, copy number, and protein overexpression.
Patients and Methods: In a cohort of consecutive patients with
lung adenocarcinoma, polymerase chain reaction and direct se-
quencing (n  89) were conducted through exons 18 to 21. Fluo-
rescence in situ hybridization (FISH) (n 89) and single-nucleotide
polymorphism (SNP) array 6.0 (n 77) were used to detect the gene
copy number. The protein expression of EGFR was detected by
standard immunohistochemistry (IHC) (n  89).
Results: Fifty-nine (66.3%) patients harbored somatic mutations of
EGFR in tyrosine kinase domain, 55.1% were positive by IHC and
44.9% were positive by FISH, and 66.2% showed gain of copy
number according to SNP array 6.0. EGFR somatic mutations are
more common in women, never smokers, and tumors with better
differentiation. Increased copy number detected by both FISH and
SNP array 6.0 analysis is significantly correlated with mutations of
EGFR.
Conclusions: The EGFR somatic mutation rate is significantly
higher in Chinese patients with lung adenocarcinoma than western
countries. Nevertheless, we found comparable FISH and IHC-
positive rates between different ethnics. Considering that FISH may
be affected by tumor heterogeneity and other factors, SNP array 6.0
analysis is a good alternative method to detect EGFR copy number
variations.
Key Words: NSCLC, Adenocarcinoma, EGFR, Mutation, Copy
number variation.
(J Thorac Oncol. 2011;6: 1016–1021)
Lung cancer is one of the most common malignancies andis the leading cause of cancer-related death worldwide.1,2
The global 5-year survival rates of non-small cell lung cancer
(NSCLC) which accounts for 80% of lung cancer remains
low, ranging from 10 to 15%.2,3 Novel targeted agents in-
cluding gefitinib and erlotinib acting on the adenosine
triphosphate-binding pocket of epidermal growth factor re-
ceptor (EGFR) tyrosine kinase domain has emerged as effec-
tive agents in treating NSCLC. In patients with NSCLC, these
drugs lead to tumor regression in 10 to 20% patients with
mild toxicity.4–6 A higher response rate was observed in
some patients with clinical characteristics including women,
never smokers, Asian, adenocarcinoma histotype, and skin
toxicity.7 Nevertheless, clinical characteristics are not reliable
in predicting candidate patients receiving EGFR tyrosine
kinase inhibitors (TKIs).8 Thus, some patients potentially
responsive to EGFR TKIs may be excluded.
Biological markers that may predict the response to
EGFR TKIs includes EGFR tyrosine kinase domain muta-
tions, increased copy number, and protein overexpression.
Patients harboring activating mutations in the tyrosine kinase
domain (exons 18–21) were found to be particularly sensitive
to TKIs and with a good prognosis irrespective of therapy.9–12
The clinical characteristics of patients carrying EGFR muta-
tions are the same with that of patients who are responsive to
TKIs, suggesting that the EGFR mutations in exons 18 to 21
are the best biological feature that predicts response to TKIs.
Nevertheless, reliable tumor tissue that can be used for
sequencing is not available in many cases. Furthermore, an
obvious part of patients with EGFR mutations does not
respond to TKIs.9,13,14 On the other hand, several clinical
trials have suggested that EGFR copy number detected by
fluorescence in situ hybridization (FISH) may predict the
patients with a better response to EGFR TKIs.15–17 Others
reported that increased EGFR copy number is associated with
EGFR mutation.18 Furthermore, it is believed that EGFR
protein expression in tumor tissue detected by immunohisto-
chemistry (IHC) should be the marker of response to mono-
clonal antibodies and EGFR TKIs.
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In this study, we investigated the association of EGFR
somatic mutation, gain of copy number, and protein expres-
sion with clinicopathologic features in lung adenocarcino-
mas. To obtain more critical information than previous stud-
ies, we conducted both FISH assay and single-nucleotide
polymorphism (SNP) array 6.0 to identify the EGFR gene
copy number variations (CNVs). In the meantime, polymer-
ase chain reaction (PCR) and direct sequencing of the ty-
rosine kinase domain of EGFR and standard IHC were also
conducted in the same cohort of patients. The comprehensive
analysis of EGFR gene using standard and new methods
would offer us the opportunity to further explore the gene
status.
PATIENTS AND METHODS
Patients and Tissues
Primary tumor samples were obtained from 224 con-
secutive patients with lung adenocarcinoma who underwent
potentially curative pulmonary resection at the Department of
Thoracic Surgery, Fudan University Shanghai Cancer Centre
from January 2008 to June 2009. Patients enrolled in this
study were based on pathologic diagnosis of lung adenocar-
cinoma, each sample containing a minimum of 70% tumor
cells as determined by study pathologists, with the absence of
neoadjuvant treatment, and the availability of sufficient tissue
to examine molecular abnormalities including gene mutation
and copy number alterations. Eighty-nine patients were in-
cluded in this study. Approval was given in advance by our
institutional review board, and all patients gave written in-
formed consent.
RNA Extraction and EGFR Mutational Analysis
Frozen tissue of tumor specimens was grossly dissected
into TRIZOL (Invitrogen, Life Technologes, Carlsbad, CA),
followed by total RNA extraction using standard protocol.
Reverse-transcription PCR was performed after total RNA
was isolated. The most common mutated EGFR tyrosine
kinase domain (exons 18–21) was amplified by PCR and the
products were directly sequenced.
Fluorescence In Situ Hybridization
EGFR gene copy number per cell was detected on forma-
lin-fixed paraffin-embedded specimens using LSI EGFR Spec-
trum orange/CEP7 Spectrum green probe (Vysis; Abbott Labo-
ratories, Abbott Park, IL) according to the manufacturer’s
protocol. FISH was performed on the same tissue area as other
tests. At least 50 cells were analyzed for each case by two
pathologists. The EGFR gene copy number was classified ac-
cording to published criteria as disomy, low polysomy (4
copies of EGFR in 40% of cells), high polysomy (4 copies
of EGFR in 40% of cells), or gene amplification (homog-
enously staining regions with15 copies in10% of cells or a
gene/chromosome ratio per cell of 2).17,19
SNP Array 6.0 Analysis
DNA samples were genotyped with Affymetrix Ge-
nome-Wide Human SNP array 6.0 microarrays. All proce-
dures, including target preparation, hybridization, washing,
staining, and scanning, were done according to the manufac-
turer’s protocol. Affymetrix Power Tools software package
(http://www.affymetrix.com) was used for summarizing probe
set signals, genotype calling, and quality control analysis. Arrays
with call rate less than 86% (birdseed v2) or contrast quality
control less than 0.4 were excluded for further analysis. We
called CNVs with PennCNV,20 a hidden Markov model algo-
rithm combining log R ratio and B allele frequency. The refer-
ence clustering file used was the one provided in the PennCNV-
Affy package (generated with HapMap data). CNVs called by
PennCNV are with copy numbers of 0 (loss), 1 (loss), 2 (nor-
mal), 3 (gain), and 4 (gain). For gene-level DNA copy numbers,
we averaged the copy numbers of all CNVs that covered one
gene, weighted by the lengths of their overlapping regions with
the gene.
IHC Staining
Paraffin-embedded tissue sections were analyzed for
EGFR protein expression by IHC using EGFR antibody
(Bioworld Technology, Inc., St. Louis Park, MN). Prepara-
tions were assessed by two observers in blind. Samples with
more than 10% tumor cells showing membranous staining of
any intensity were classified as EGFR positive as reported
before.21
Statistical Analysis
The association between EGFR status and clinical and
biological characteristics was analyzed by 2 or Fisher’s
exact test. Age differences were compared using t test for
independent samples. All data were analyzed using the Sta-
tistical Package for the Social Sciences Version 16.0 Soft-
ware (SPSS Inc., Chicago, IL). The two-sided significance
level was set at p less than 0.05.
RESULTS
Patient Characteristics
Eighty-nine patients with lung adenocarcinoma were
enrolled in this study, including 49 men and 40 women
(average, 59 years; range, 40–79 years). Thirty-nine were
smokers and 50 were nonsmokers, accounting for 44% and
56%, respectively. The detailed information on tumor differ-
entiation, stage, tumor size, location, and metastatic status is
listed in Table 1.
Chinese Patients with Lung Adenocarcinoma
have Different EGFR Mutation Spectrum
The evaluation of EGFR mutations were successful in
all cases (n  89). In this cohort of patients, 59 (66.3%) were
identified to harbor EGFR kinase domain mutations. Among
these mutations, 28 were exon 19 deletion, and 26 were exon
21 missense mutation (L858R). There was a significant
higher rate of EGFR mutations in women (82.5% versus
53.1%, p  0.003) and those who never smoked (78.0%
versus 51.3%, p  0.008). In the subgroup of those who
never smoked, the mutation rate in women and men was
82.5% and 60%, respectively, with a nonsignificant statistical
difference, consistent with our previous observation.22 Specifi-
cally, we found a trend toward higher mutation rate in well-
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differentiated tumors (87.5%), when compared with moderately
(69.8%) and poorly (50%) differentiated tumors (p 0.03). No
significant association of EGFRmutation rate with tumor stages
was found (Table 2).
FISH and SNP Array 6.0 Showed Similar
Correlation with Clinicopathological Features
EGFR copy number were analyzed by both FISH (n 
89) and SNP array 6.0 (n  74). Eleven cases that initially
failed in FISH experiment underwent modified FISH proce-
dure and finally succeeded. Among the 89 samples undergone
FISH experiment, there were 40 (44.9%) FISH-positive cases
and seven (7.8%) with gene amplification (Figure 1). The
association between FISH results and clinicopathologic fea-
tures was not significant. Nevertheless, there was a trend of
more FISH-positive cases in stages III and IV than in stages
I and II patients (55.4% versus 36%, p  0.055) with a
borderline p value. The cases with gain of copy number was
TABLE 1. The Clinical Characteristics of 89 Chinese Patients
with Lung Adenocarcinoma
No. Percentage
Age at diagnosis (yr), median (range) 59 (40–79) —
Gender
Male 49 55
Female 40 45
Smoking habit
Ever smoker 39 44
Never smoker 50 56
Differentiation
Well 16 18
Moderate 41 46
Poor 30 34
Unknown 2 2
Tumor stage
I 42 47
II 8 9
III 38 43
IV 1 1
Tumor size
3 cm 40 47
3–5 cm 33 38
5 cm 13 15
Location of the tumor in the lungs
Bronchus 0 0
Upper lobe 52 58
Middle lobe 12 14
Lower lobe 25 28
Nodal status
N0 52 58
N1–N3 37 42
Metastasis status
M0 88 98.9
M1 1 1.1
Those who smoked fewer than 100 cigarettes in their lifetime were defined as never
smokers; otherwise, they were considered as smokers. The tumor size refers to the
maximal diameter of the tumor.
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49 (66.2%) detected by SNP array 6.0 (Figure 2). There were
significantly more gain of copy number cases in moderately
differentiated tumors (p  0.016). Coincidently, there were
more cases with increased copy number in stages III and IV
than in stages I and II patients (75.7% versus 57.1%, p 
0.059) when analyzed by SNP array 6.0 data (Table 2).
Considering FISH as the gold standard for detecting EGFR
copy number, the sensitivity and specificity of SNP array 6.0
are 94.6% and 63.2%, with a positive predictive value of
71.4% and negative predictive value of 92.3%.
EGFR IHC Staining Showed No Correlation
with Other Parameters
EGFR IHC staining was positive in 49 (55.1%) of the
89 tumor specimens. No significant correlation in clinico-
pathologic characteristics was observed.
The Association between EGFR Mutation, CNV,
and Protein Expression
The EGFR mutation status was correlated with CNVs
detected by both FISH (p  0.001) and SNP array 6.0 (p 
0.001). The two methods to detect copy number of EGFR
were highly coincident (p  0.001). Nevertheless, the EGFR
protein expression detected by IHC and gene amplification
detected by FISH were not correlated with any other param-
eters (Table 3).
DISCUSSION
The selection of patients who would be responsive to
EGFR TKIs is mainly based on mutational and copy number
analysis in clinic at present. Nevertheless, different research-
ers from different institutions have diverse opinions as to
which is the best predictive biomarker. It would be difficult to
get conclusion before prospective randomized trials are fin-
ished. The purpose of our study is to illustrate the gene status
through different detective methods. We further explored the
correlation between different gene status defined by these
methods. Previous studies have focused on assessment of the
EGFR status using EGFR kinase domain sequencing, FISH,
and IHC in different ethics.23–26 The use of SNP array to
analyze gene copy number is also reported before.27,28 In this
study, we used FISH and SNP array as mutual validation
methods to assess EGFR CNV. To our knowledge, this is the
first comprehensive study including sequencing, FISH, SNP
array 6.0, and IHC in the same cohort of patients with lung
adenocarcinoma.
Activating mutation of EGFR tyrosine kinase domain
has been considered as the primary predictor of response to
FIGURE 1. Cases of EGFR FISH-positive samples. A, Clusters of EGFR (red) spots in the nuclei. B, Nuclei with numerous EGFR
spots, with the gene/chromosome ratio more than 2. C, High polysomy represented as comparable number of gene and
chromosome, with 4 copies of EGFR in more than 40% of nuclei counted. EGFR, epidermal growth factor receptor; FISH,
fluorescence in situ hybridization.
FIGURE 2. EGFR gene copy number alterations in lung adenocarcinomas detected by SNP array 6.0. Copy numbers of four
probes of EGFR are shown. Any of the four probes that marked red is considered as gain of copy number. EGFR, epidermal
growth factor receptor; SNP, single-nucleotide polymorphism.
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TKIs. Patients carrying the EGFR mutation were especially
sensitive to TKIs with response rate up to 82%.10,18,29 The
rate of EGFR mutation in our study is comparable with other
studies from East Asia with lung adenocarcinoma, which
ranges from 40 to 64%.10,18,24,30–32 The mutation spectrum of
EGFR also showed a significant trend toward more mutations
in women and never smokers. Our previous study revealed
that the smoking habit may bias the mutation rate between
women and men. In fact, there are comparable mutation rate
between women and men with lung adenocarcinoma in Chi-
nese patients who never smoked.33 This study showed that
there are more EGFR mutations in well-differentiated tumors
than moderate and poorly differentiated tumors (p  0.03).
This result partially explained why it is reported that patients
with mutated EGFR had a better prognosis than those with
wild-type EGFR.34,35 In such cases, the mutation status could
be a bias factor, whereas the tumor differentiation may be the
real factor that correlated with prognosis. It is widely reported
that the EGFR mutation is correlated with increased gene
copy number detected by FISH.23,36,37 In our analysis, EGFR
mutation is significantly correlated with increased copy num-
ber detected both by FISH (p  0.001) and SNP array 6.0
(p  0.001).
Enlightened by the human epidermal growth factor
receptor (HER2) gene copy number as predictive marker in
breast cancer therapy,38,39 EGFR copy number detection has
been used widely in NSCLC.8,17 The standard method to
detect EGFR copy number is FISH using the commercial
Vysis fluorescent probes. The predictive value of EGFR
FISH to TKIs treatment has been described previously. Be-
cause of the unavailability of frozen tissue to perform muta-
tional analysis, FISH experiment performed on formalin-
fixed paraffin-embedded slides can be achieved in almost all
the cases. In our study, 44.9% were FISH positive and 7.8%
showed EGFR gene amplification. Different from the much
higher EGFR mutation rate in East Asian patients, the FISH-
positive rate was similar with the studies performed in west-
ern population (31–45%).13,40,41 Although EGFR copy num-
ber can be quantitatively assessed by FISH, there are also
limitations. Generally, 50 cells are analyzed in a FISH ex-
periment to detect EGFR copy number. Nevertheless, tumor
heterogeneity may be obvious in many cases, thus confusing
the interpretation of the result. Therefore, standardized inter-
pretation method of EGFR FISH should be established,
which should include selected tumor nuclei, no overlapping
nuclei, and as much fields as possible. Herein, we introduced
SNP 6.0 array to detect EGFR gene copy number. As the
array-based analysis is a reflection of all nucleotide extracted
from samples, it could be valuable to detect CNVs. In our
assay, the gain of copy number detected by SNP array 6.0 is
significantly correlated with EGFR FISH positive and muta-
tion. The copy number detected by FISH and SNP array 6.0
is consistent in most of samples in our study. The IHC results
showed no correlation with other features in this study. The
IHC positive is a marker of higher response rate in other
studies.37 Nevertheless, because of the difficulties in quanti-
tative measuring and conflicting results of many studies, the
IHC is not a good marker for responsiveness to EGFR TKIs
in patients with NSCLC.
CONCLUSION
In conclusion, in our study, we made a comprehensive
analysis of EGFR gene status in lung adenocarcinoma. We
integrated different detective methods to have a full under-
standing of the EGFR gene status. The EGFRmutation rate in
our study is much higher than western population, whereas
the FISH-positive rate is similar. EGFR mutation status is
significantly correlated with increased copy number detected
by both FISH and SNP array 6.0. The SNP array 6.0 is a
valuable method to detect EGFR copy number.
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